Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Please make sure you go through the Terms and Conditions and familiarize yourself with them, as it is important
This can reduce the appearance of fine lines and wrinkles while making skin firmer and more elastic
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
Research discussions may explore cellular signaling behavior, structural interaction models, and experimental repair-pathway frameworks without implying outcomes or approved applications
While the drug reduced inflammation markers as expected, it showed no meaningful reduction in major adverse cardiovascular events (MACE)including cardiovascular death, non-fatal heart attack, or non-fatal stroke
